NYSE · Healthcare · Financials
Pfizer, Inc. (PFE) financial statements and cash flow.
Revenue, profitability, balance-sheet strength, and cash generation for PFE. Market data source · as of 2026-06-28.
Section freshness
Price Aug 19, 1:15 PM EDT · Statements Jun 27, 8:00 PM EDT
Financial read
PFE latest financial snapshot.
Start with the latest reported values below. Deeper quarterly and annual statement tables follow when supplied.
Net income
-$248.00M
-109.2% QoQ
Free cash flow
$302.00M
-86.1% QoQ
Balance sheet coverage
PFE balance sheet summary
Assets, liabilities, liquidity, debt, and equity sit beside income and cash-flow tables so the statement history reads as one model-ready dataset.
20 quarterly · 4 annual rows · Market data source · as of 2026-06-28
Latest period
Q2 FY2026
20 quarterly · 4 annual rows
Assets / liabilities
$201.13B
Liabilities $115.64B
Cash / debt
$976.00M
Net cash -$62.22B
Equity / working capital
$85.19B
Working capital $8.71B
Financial statements
PFE statement coverage.
Income statement, balance sheet, and cash-flow figures for PFE, with quarterly and annual history in the tables below.
Data last updated
Jun 27, 2026
Income periods
24
Balance-sheet periods
24
Cash-flow periods
24
Quarterly and annual PFE statements, sourced from Market data source · as of 2026-06-28.
Financial statement period
PFE statement history
Market data source · as of 2026-06-28 · Data last updated: Jun 27, 2026
Income statement
Quarterly and annual rows for revenue, operating leverage, earnings quality, and margin direction.
| Period | Revenue | Gross profit | Operating income | Interest income | Continuing ops | Net income | Comprehensive income | Net margin | Revenue QoQ | Net income QoQ |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | -$248.00M | -109.2% | ||||||||
| Q1 FY2026 | $2.69B | +263.1% | ||||||||
| Q4 FY2025 | -$1.65B | -146.5% | ||||||||
| Q3 FY2025 | $3.54B | +21.7% | ||||||||
| Q2 FY2025 | $2.91B | -1.9% | ||||||||
| Q1 FY2025 | $2.97B | +623.7% | ||||||||
| Q4 FY2024 | $410.00M | -90.8% | ||||||||
| Q3 FY2024 | $4.46B | +10790.2% |
Balance sheet
Balance-sheet history for assets, liabilities, liquidity, debt, equity, and shares outstanding.
| Period | Cash | Current assets | Current liabilities | Total assets | Total liabilities | Total debt | Capital leases | Total equity | Shares | Debt QoQ |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $976.00M | $41.36B | $32.65B | $201.13B | $115.64B | $63.19B | $85.19B | -2.0% | ||
| Q1 FY2026 | $1.70B | $42.82B | $34.35B | $207.62B | $117.21B | $64.45B | $90.10B | -0.5% | ||
| Q4 FY2025 | $1.14B | $42.90B | $36.98B | $208.16B | $121.39B | $64.80B | $86.48B | +5.0% | ||
| Q3 FY2025 | $1.34B | $46.92B | $36.60B | $208.73B | $115.64B | $61.71B | $92.80B | -0.1% | ||
| Q2 FY2025 | $1.64B | $43.70B | $37.73B | $206.09B | $117.08B | $61.80B | $88.69B | -0.5% | ||
| Q1 FY2025 | $1.43B | $45.86B | $36.45B | $208.03B | $117.39B | $62.11B | $90.34B | -3.5% | ||
| Q4 FY2024 | $1.04B | $50.36B | $42.99B | $213.40B | $124.90B | $64.35B | $88.20B | -4.9% | ||
| Q3 FY2024 | $1.09B | $43.22B | $43.21B | $219.48B | $126.92B | $67.70B | $92.29B | -2.5% |
Cash flow
Operating cash generation, capital expenditure, free cash flow, buybacks, dividends, and cash movement.
| Period | Operating cash flow | CapEx | Free cash flow | Net income | Stock comp | Debt issuance | Dividends paid | Buybacks | Change in cash | FCF QoQ |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $835.00M | $533.00M | $302.00M | -$248.00M | $4.90B | -86.1% | ||||
| Q1 FY2026 | $2.62B | $436.00M | $2.18B | $2.69B | — | -51.6% | ||||
| Q4 FY2025 | $5.35B | $845.00M | $4.50B | -$1.65B | $4.89B | +12.5% | ||||
| Q3 FY2025 | $4.60B | $602.00M | $4.00B | $3.54B | -$1.00M | +433.4% | ||||
| Q2 FY2025 | -$582.00M | $618.00M | -$1.20B | $2.91B | $4.89B | -167.8% | ||||
| Q1 FY2025 | $2.33B | $564.00M | $1.77B | $2.97B | — | -69.5% | ||||
| Q4 FY2024 | $6.72B | $917.00M | $5.80B | $410.00M | $4.82B | -4.3% | ||||
| Q3 FY2024 | $6.71B | $651.00M | $6.06B | $4.46B | — | +350.7% |
Valuation and returns
- Enterprise value
- $222.72B
- TECHi computed
- Return on equity
- 5.09%
- Market data source
- Return on assets
- 2.15%
- Market data source
- Debt / equity
- 0.74
- Current ratio 1.27
Ratio values use provider-attributed fields when available and otherwise fall back to TECHi statement math from the visible rows on this page.
Annual revenue and income multiples
Annual sales and income multiple reads use the latest annual statement when available, then fall back to trailing-twelve-month statement math from the visible quarterly rows.
- Annual income base
- $7.77B
- Annual statement 2025-12-31
- Market cap / annual income
- 20.65
- Live market value divided by annual net income
Market capitalization bridge
TTM valuation multiples
Live market value is matched against trailing-twelve-month statement bases first so the multiple moves with the tape instead of anchoring to stale fiscal-year rows.
Profit multiples
Revenue, net income, and free cash flow
Quarterly statement rows, shown on one common dollar scale so margin compression and cash conversion stand out quickly.
Efficiency
Growth vs cost pressure
Latest quarter expense mix
Profit bridge
Other income statement lines
Balance sheet · Q2 FY2026
- Cash & equivalents
- $976.00M
- Total debt
- $63.19B
- Net cash
- -$62.22B
- Net debt position
- Total equity
- $85.19B
Balance sheet detail
- Current assets
- $41.36B
- Current liabilities
- $32.65B
- Inventory
- $9.95B
- Receivables
- $12.49B
- Property, plant & equipment
- $19.03B
- Current debt
- $2.70B
- Long-term debt
- $60.49B
Debt and liquidity
Cash + short-term investments + receivables / current liabilities
Cash generation
- Operating cash flow
- $835.00M
- Capital expenditure
- $533.00M
- Free cash flow
- $302.00M
- Capital returned
- $4.90B
- Buybacks + dividends paid
Cash-flow detail
- Depreciation & amortization
- $1.62B
- Investing cash flow
- $2.11B
- Financing cash flow
- -$3.66B
- Dividends paid
- $4.90B
Cash flow read
PFE runs cash-flow positive.
PFE is generating $302.00M of free cash, which funds buybacks (—) and dividends ($4.90B) without leaning on the balance sheet. Watch the gap between FCF and net income — a widening gap is usually working-capital noise; a persistent gap is a signal.
Frequently asked
Common questions.
What financial data is available for PFE?
The PFE Financials page renders only the current income-statement, balance-sheet, cash-flow, or fund rows supplied for Pfizer, Inc.. Missing modules and empty line items are omitted.
How current are PFE's financial statements?
Each visible statement row keeps its reported period and provider attribution. The route redirects to the main quote when no usable financial or fund data remains.
What is Pfizer, Inc.'s reported net margin?
Pfizer, Inc.'s fresh reported margin field is 4.72%. The Financials page shows the supporting period data currently available for PFE.